Esperite N.V. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2012
2013
2014
2015
2016
2017
Net Income before Extraordinaries
17,103.00
3,513.00
5,005.00
7,207.00
8,538.00
12,883
Depreciation, Depletion & Amortization
3,214.00
2,810.00
2,885.00
2,692.00
2,944.00
2,783
Other Funds
-
-
1,450.00
-
-
5,458
Funds from Operations
541.00
737.00
1,126.00
5,141.00
5,137.00
4,654
Changes in Working Capital
1,845.00
893.00
1,942.00
4,960.00
6,042.00
1,135
Net Operating Cash Flow
2,386.00
156.00
3,068.00
181.00
905.00
3,519
Capital Expenditures
1,717.00
647.00
1,774.00
2,342.00
1,462.00
Sale of Fixed Assets & Businesses
143.00
2,499.00
77.00
22.00
-
Net Investing Cash Flow
1,574.00
1,852.00
1,697.00
2,318.00
1,386.00
Cash Dividends Paid - Total
564.00
-
-
-
-
Issuance/Reduction of Debt, Net
184.00
208.00
208.00
590.00
67.00
Net Financing Cash Flow
748.00
492.00
1,658.00
1,790.00
67.00
Net Change in Cash
64.00
1,476.00
6,460.00
648.00
539.00
Free Cash Flow
1,053.00
219.00
4,189.00
1,874.00
458.00
Deferred Taxes & Investment Tax Credit
-
-
-
-
1,197.00
12
Other Sources
-
-
-
2.00
76.00
Change in Capital Stock
-
284.00
-
1,200.00
-
Exchange Rate Effect
-
40.00
37.00
61.00
9.00

About Esperite

View Profile
Address
Herengracht 282
Amsterdam Noord-Holland 1016 BX
Netherlands
Employees -
Website http://www.esperite.com
Updated 07/08/2019
Esperite NV engages in regenerative and predictive medicine. It operates through the following business segments: The extraction and storage of adult human stem cells, Research and Development, Predictive medicine, and Other types of products and services. The extraction and storage of adult human stem cells segment refers to the tem cells collected from the umbilical cord blood, and the umbilical cord itself, at birth and from adipose tissue.